Journal of Cardiac Failure

Heart Failure with Preserved Ejection Fraction (HFpEF) is a major healthcare challenge, and its prevalence is rising globally. Women have twice the lifetime risk of HFpEF when compared to men. Given the unique sex-specific risk factors in women and the sex-related differences in traditional risk factors, there are sex-related variations in pathophysiology and treatment response. In this joint publication in the Journal of Cardiac Failure and the American Journal of Preventive Cardiology, the authors synthesize and summarize existing data to address these and other gaps in knowledge. Learn more: https://bit.ly/431HUVx

New Science Alert! Heart Mate 3 (HM3) Left Ventricular Assist Devices (LVADs) are associated hemodynamic-related events (HDRE) like right ventricular (RV) failure, despite fewer hemocompatibility-related adverse events (HRAE). In this latest study, out now in the Journal of Cardiac Failure, the investigators analyzed the effects of a novel, upfront RV protection strategy to mitigate such hemodynamic risks. The strategy focused on hemodynamic, ventilatory, and pharmaceutical optimization to achieve post-operative RV protection. The authors found that the strategy resulted in significantly greater survival free from HDRE or HRAE. Learn more: https://bit.ly/3CEDDN7

The latest Brief Report in the Journal of Cardiac Failure presents a sub-analysis of the REBALANCE-HF trial. REBALANCE-HF was a prospective, multicenter, randomized, double-blinded, sham-controlled trial of endovascular, transcatheter, right-sided greater splanchnic nerve (GSN) ablation for volume management. In the current sub-study found that that permanent GSN ablation reduced stressed blood volume, thus having the beneficial hemodynamic effect of reducing right atrial pressure and pulmonary capillary wedge pressure at rest and on exercise. Read more: https://bit.ly/4hXV75Q

Hot off the presses is this this new Perspectives piece from Dr. Nir Uriel, Dr. Manreet Kanwar, Dr. Gabriel Sayer and others, out now in the Journal of Cardiac Failure and simultaneously published with the ongoing THT 2025 conference! The authors reflect on the challenges of the current Advanced Heart Failure Fellowship structure, and propose melding Critical Care training into these programs, in centers with and without advanced heart failure therapies. Learn more here: https://bit.ly/4gCTJof

The profile of patients hospitalized with acute heart failure (HF) has evolved over time from patients with severe pump failure to those with advanced age, obesity and comorbidity-related cardiovascular dysfunction combined with neurohormonal and inflammatory dysregulation. In this State-of-the-Art Review on the management of acute HF, the authors describe the changing paradigm of managing acute HF patients with rapidly escalating doses of neurohormonal blockers as well as anti-inflammatory treatments. Learn more: https://bit.ly/3WYvHNk

Carotid Baroreflex Activation Therapy (BAT) is an emerging device therapy in heart failure with reduced ejection fraction (HFrEF) that modulates baroreceptor nerve activity. Clinical trial data has shown that it can improve exercise capacity, quality of life and functional status in HFrEF. In this Brief Report, out now in the Journal of Cardiac Failure, Jacob Abraham, MD and his co-investigators have conducted an analysis of a real-world, national administrative database to demonstrate association of BAT with reductions in all-cause, CV, non-CV, and HF hospital visits and length of stay. Learn more here: https://bit.ly/4aW92Y2

New science alert! In heart failure with reduced ejection fraction (HFrEF), guideline-directed medical therapy, resynchronization therapy, interventions for mitral regurgitation and various surgical left ventricular (LV) restoration techniques have been developed with the aim of tackling the LV remodeling inherent in HFrEF. However, there are limits to efficacy and, in the case of surgical interventions, considerable risk. The AccuCinch Transcatheter LV Restoration (TLVR) System is a transcatheter LV reshaping device under investigation, that might play a role in this space. In this new JCF Ignite! Article, out now in the Journal of Cardiac Failure, authors Yogita Rochlani, MD & colleagues explore the existing data behind the device, discuss the ongoing CorCinch-HF trial and evaluate the competing benefits and limitations of this therapy. Read more here: https://bit.ly/3CC3WUb

Is transthyretin (TTR) biology (misfolding and aggregation) the sole driver of disease progression in transthyretin amyloid cardiomyopathy (ATTR-CM) or are other mechanisms also at play? In an era of multiple effective disease-modifying therapies that target TTR biology, is selecting one agent over another the most important thing in ATTR-CM, or is enhancing timely diagnosis and treatment of this vulnerable population preferable? Learn more here: https://bit.ly/42MGNZN

Therapeutic trials in Heart Failure with Preserved Ejection Fraction (HFpEF) have generally failed to demonstrate improvements in hemodynamic measures of peak exercise performance. In the latest JCF Ignite! article, out now in the Journal of Cardiac Failure, and coordinated with his talk at the 2025 Technologies and Heart Failure Therapeutics (#THT2025) Conference, Dr. Yogesh Reddy of the Mayo Clinic argues that these parameters are probably less relevant than hemodynamic measures at submaximal exercise, which probably better reflect effort with activities of daily living. He further suggests that improvements in these hemodynamic measures without true disease modification driving them are unlikely to bring about meaningful improvements in outcomes. Read this article here: https://bit.ly/4hKmHDS

Acute heart failure (HF) differs from chronic HF, especially in patients with heart failure with mildly-reduced and preserved ejection fraction (HFmrEF/HFpEF), due to marked neurohormonal and adrenergic activation in the former. This neurohormonal activation serves as a target of therapeutic action where in initiation and rapid uptitration of neurohormonal blockers in patients with HFmrEF/HFpEF and acute HF can have a beneficial effect. In the latest Perspectives piece, out now in the Journal of Cardiac Failure, the authors discuss this topic by exploring the data from recent acute and chronic HF trials. Learn more here: https://bit.ly/4gF4ned